Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Evgin, L., Ilkow, C. S, Bourgeois-Daigneault, M., de Souza, C. T., Stubbert, L., Huh, M. S, Jennings, V. A, Marguerie, M., Acuna, S. A, Keller, B. A, Lefebvre, C., Falls, T., Le Boeuf, F., Auer, R. A, Lambris, J. D., McCart, J A., Stojdl, D. F, & Bell, J. C Molecular Therapy - Oncolytics, 3:16027, 2016.
Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. [link]Paper  doi  abstract   bibtex   
The systemic delivery of therapeutic viruses, such as oncolytic viruses or vaccines, is limited by the generation of neutralizing antibodies. While pseudotyping of rhabdoviruses with the lymphocytic choriomeningitis virus glycoprotein has previously allowed for multiple rounds of delivery in mice, this strategy has not translated to other animal models. For the first time, we provide experimental evidence that antibodies generated against the lymphocytic choriomeningitis virus glycoprotein mediate robust complement-dependent viral neutralization via activation of the classical pathway. We show that this phenotype can be capitalized upon to deliver maraba virus pseudotyped with the lymphocytic choriomeningitis virus glycoprotein in a Fischer rat model in the face of neutralizing antibody through the use of complement modulators. This finding changes the understanding of the humoral immune response to arenaviruses, and also describes methodology to deliver viral vectors to their therapeutic sites of action without the interference of neutralizing antibody.
@article{Evgin:2016kbb,
  abstract = {The systemic delivery of therapeutic viruses, such as oncolytic viruses or vaccines, is limited by the generation of neutralizing antibodies. While pseudotyping of rhabdoviruses with the lymphocytic choriomeningitis virus glycoprotein has previously allowed for multiple rounds of delivery in mice, this strategy has not translated to other animal models. For the first time, we provide experimental evidence that antibodies generated against the lymphocytic choriomeningitis virus glycoprotein mediate robust complement-dependent viral neutralization via activation of the classical pathway. We show that this phenotype can be capitalized upon to deliver maraba virus pseudotyped with the lymphocytic choriomeningitis virus glycoprotein in a Fischer rat model in the face of neutralizing antibody through the use of complement modulators. This finding changes the understanding of the humoral immune response to arenaviruses, and also describes methodology to deliver viral vectors to their therapeutic sites of action without the interference of neutralizing antibody.},
  added-at = {2017-12-08T05:18:19.000+0100},
  affiliation = {Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.},
  author = {Evgin, Laura and Ilkow, Carolina S and Bourgeois-Daigneault, Marie-Claude and de Souza, Christiano Tanese and Stubbert, Lawton and Huh, Michael S and Jennings, Victoria A and Marguerie, Monique and Acuna, Sergio A and Keller, Brian A and Lefebvre, Charles and Falls, Theresa and Le Boeuf, Fabrice and Auer, Rebecca A and Lambris, John D. and McCart, J Andrea and Stojdl, David F and Bell, John C},
  biburl = {https://www.bibsonomy.org/bibtex/2aaff12e524ba05822e3e85a8cc38700c/lambris},
  date-added = {2017-12-08T04:15:47GMT},
  date-modified = {2017-12-08T04:17:37GMT},
  doi = {10.1038/mto.2016.27},
  interhash = {a92bed87a39ab377095329ae23e7d4ba},
  intrahash = {aaff12e524ba05822e3e85a8cc38700c},
  journal = {Molecular Therapy - Oncolytics},
  keywords = {imported},
  language = {English},
  pages = 16027,
  pmcid = {PMC5111574},
  pmid = {27909702},
  rating = {0},
  timestamp = {2017-12-08T05:18:19.000+0100},
  title = {{Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.}},
  uri = {\url{papers3://publication/doi/10.1038/mto.2016.27}},
  url = {http://linkinghub.elsevier.com/retrieve/pii/S2372770516300638},
  volume = 3,
  year = 2016
}

Downloads: 0